Results 301 to 310 of about 11,841,902 (391)

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage. [PDF]

Int J Mol Sci
Filippenkov IB, Shpetko YY, Ales DA, Stavchansky VV, Denisova AE, Yuzhakov VV, Fomina NK, Gubsky LV, Andreeva LA, Myasoedov NF, Limborska SA, Dergunova LV.   +11 more
europepmc   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Employing diclofenac sodium as a novel therapeutic frontier for Staphylococcus epidermidis infections. [PDF]

Sci Rep
Abo-Kamar AM, Abdelaziz AA, Ashour AE, Shaldam MA, Elekhnawy E.   +4 more
europepmc   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Specific induction of right ventricular-like cardiomyocytes from human pluripotent stem cells. [PDF]

Stem Cell Res Ther
Saito Y, Nakamura K, Katanosaka Y, Iida T, Kusumoto D, Sato R, Adachi R, Shimizu S, Kurokawa J, Akagi S, Yoshida M, Miyoshi T, Morita H, Naruse K, Nishida M, Udono H, Zhang J, Yuasa S, Kamp TJ, Ito H.   +19 more
europepmc   +1 more source

Characterizing epithelial‐mesenchymal transition‐linked heterogeneity in breast cancer circulating tumor cells at a single‐cell level

Molecular Oncology, EarlyView.
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa, Julia Richert, Tomasz Stokowy, Alicja Staśczak, Mariusz Szajewski, Maciej Ciesielski, Petra M. Grešner, Bartłomiej Tomasik, Łukasz Arcimowicz, Agnieszka Stankiewicz, Grażyna Suchodolska, Elżbieta Senkus, Wiesław Kruszewski, Anna J. Żaczek, Aleksandra Markiewicz   +14 more
wiley   +1 more source

Five CGD-Linked CYBB Mutations in Chinese Patients: Insights Into Predicting IFN-γ Treatment Efficacy. [PDF]

J Clin Immunol
Liao YX, Xia L, Liu P, Li XH, Liu LP, Xu L, Tian D, Shi DL, Guo XM, Mei X, Okada S, Liu YB, Wang FF, Wang XC, Zhao C, Fan XH, Sun JQ, Liu TF, Ling Y.   +18 more
europepmc   +1 more source

The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity

Molecular Oncology, EarlyView.
Natural killer (NK) cells play a central role in anti‐melanoma immunity. However, melanoma cells adapt during co‐culture by upregulating CIITA and MHC II in response to interferon gamma (IFNγ), thereby evading NK‐cell lysis. Blocking IFNγ signaling or treatment with dimethyl fumarate/simvastatin counteracts this immune escape and maintains NK‐cell ...
Lena C. M. Krause, Rixa‐Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski   +6 more
wiley   +1 more source